Banner Photo
 
Directory of Clinical Studies

ConditionStudyIDTitleStatus
HIV (Pediatric), Pediatric StudiesAI424-451Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)Recruiting
HIV (Pediatric), Pediatric StudiesAI424-452Safety Sudy of Atazanavir Capsules in the Treatment of HIV in Patients Ages 6 - 18 YearsRecruiting
Healthy VolunteersAI443-006Study to Assess the Effect of BMS-791325 on the Pharmacokinetics of Midazolam in Healthy SubjectsRecruiting
Hepatitis CAI444-046Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical TrialRecruiting
Hepatitis CAI444-215Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Subjects and Subjects Post-liver TransplantRecruiting
Hepatitis CAI444-216Phase III HIV/HCV Co-Infection Daclatasvir (DCV)+ Sofosbuvir (SOF)Recruiting
Hepatitis CAI444-218Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCVRecruiting
Hepatitis CAI452-008 (Substudy Part C)Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With RibavirinRecruiting
Hepatitis CAI452-016Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical TrialRecruiting
Hepatitis CAI452-030Safety and Efficacy Study in Subjects With Chronic HCV and Underlying HemophiliaRecruiting
Hepatitis CAI452-032Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIVRecruiting
Hepatitis CAI472-013A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)Recruiting
Diabetes (Adult)BCB109Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes MellitusRecruiting
CancerCA002-001Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid TumorsRecruiting
Cancer, Leukemia (Pediatric), Pediatric StudiesCA180-226A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to ImatinibRecruiting
Cancer, Leukemia (Adult)CA180-330Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world SettingRecruiting
Cancer, Leukemia (Pediatric), Pediatric StudiesCA180-372Pediatric Philadelphia Positive Acute Lymphoblastic LeukemiaRecruiting
Cancer, Leukemia (Adult)CA180-373A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid LeukemiaRecruiting
Cancer, MelanomaCA180-385Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF MutationRecruiting
Cancer, Leukemia (Adult)CA180-399Phase IIb Study of Dasatinib Versus Imatinib in Patients With CML-CP Who Have Not Achieved an Early Optimal Response to ImatinibRecruiting
Cancer, Leukemia (Adult)CA180-400This Study Will be a Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to ImatinibRecruiting
Cancer, Leukemia (Adult)CA180-406Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular ResponseRecruiting
Lung Cancer, CancerCA184-104Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and CarboplatinRecruiting
Cancer, MelanomaCA184-143A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic MelanomaRecruiting
Lung Cancer, CancerCA184-156Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy AloneRecruiting
Cancer, Melanoma (Pediatric), Pediatric StudiesCA184-178Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant MelanomaRecruiting
Cancer, Ovarian CancerCA184-201Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer PatientsRecruiting
Cancer, Solid TumorsCA186-011Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's LymphomaRecruiting
CancerCA186-017Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma or CLLRecruiting
Cancer, Multiple MyelomaCA204-006Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple MyelomaRecruiting
Cancer, Leukemia (Adult)CA204-006 (Biomarker Substudy)PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)Recruiting
Cancer, Leukemia (Adult)CA204-008Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)Recruiting
Cancer, Multiple MyelomaCA204-009Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple MyelomaRecruiting
Lung Cancer, CancerCA209-012Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)Recruiting
Cancer, Solid TumorsCA209-032A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid TumorsRecruiting
Cancer, MelanomaCA209-038Phase 1 Biomarker Study of Anti-PD-1 in Advanced MelanomaRecruiting
Cancer, Leukemia (Adult)CA209-039Safety Study of Nivolumab and Ipilimumab in Hematologic MalignancyRecruiting
Liver Cancer, CancerCA209-040Dose Escalation Study of Nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in Patients (Pts) With Advanced Hepatocellular Carcinoma (HCC) With or Without Chronic Viral HepatitisRecruiting
Cancer, MelanomaCA209-064Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)Recruiting
Lymphoma, Non Hodgkin's Lymphoma, Non Hodgkin's Lymphoma (DLBCL), CancerCA209-139Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)Recruiting
Cancer, Lymphoma, Non Hodgkin's Lymphoma, Non Hodgkin's Lymphoma (Follicular)CA209-140Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)Recruiting
Colorectal Cancer, Cancer, Colon Cancer MSI HighCA209-142A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142)Recruiting
Glioblastoma, Brain CancerCA209-143A Randomized Study of Nivolumab or Nivolumab Combined With Ipilimumab Versus Bevacizumab in Adult Subjects With Recurrent Glioblastoma(GBM)(CheckMate 143)Recruiting
Cancer, Lung CancerCA209-153A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153)Recruiting
Cancer, Leukemia (Adult)CA212-001First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell CancersRecruiting
Cancer, Multiple MyelomaCA212-002Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple MyelomaRecruiting
Cancer, Solid TumorsCA216-001Study to Evaluate the Safety and Tolerability of Weekly IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid TumorsRecruiting
Cancer, Leukemia (Adult), Non Hodgkin's Lymphoma, LymphomaCA216-002Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic LymphomaRecruiting
CancerCA216-003Study to Evaluate the Safety and Tolerability of BMS-906024 in Combination With Chemotherapy (Weekly Paclitaxel, 5FU Plus Irinotecan (FOLFIRI) or Carboplatin Plus Paclitaxel) in Subjects With Advanced or Metastatic Solid TumorsRecruiting
Cancer, Solid TumorsCA220-008Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid TumorsRecruiting
Cancer, Solid TumorsCA223-001A Phase I Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid TumorsRecruiting
CancerCA223-002Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced TumorRecruiting
CancerCA224-020Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid TumorsRecruiting
CancerCA224-022Safety Study of Anti-LAG-3 in CLL, HL and NHLRecruiting
Alzheimer’s DiseaseCN167-003Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's DiseaseRecruiting
Diabetes (Pediatric), Pediatric StudiesCV181-058Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 DiabetesRecruiting
Diabetes (Pediatric), Pediatric StudiesCV181-147A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin AloneRecruiting
Diabetes (Pediatric)CV181-153Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DMRecruiting
Diabetes (Adult)CV181-168Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 DiabetesRecruiting
Diabetes (Adult)CV181-206Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 DiabetesRecruiting
Blood Clots (Pediatric)CV185-118Study to Evaluate a Single Dose of Apixaban in Pediatric Subjects at Risk for a Thrombotic DisorderRecruiting
Diabetes (Adult), Kidney DiseaseCV202-010Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney DiseaseRecruiting
Rheumatoid ArthritisIM101-240An Observational Registry of Abatacept in Patients With Juvenile Idiopathic ArthritisRecruiting
Lupus, Lupus NephritisIM101-291Efficacy and Safety Study of Abatacept to Treat Lupus NephritisRecruiting
Rheumatoid Arthritis, Pediatric StudiesIM101-301Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)Recruiting
Psoriatic ArthritisIM101-332Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic ArthritisRecruiting
Rheumatoid ArthritisIM101-366Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled SyringeRecruiting
TransplantationIM103-076Evaluating Nulojix (Belatacept) Long-Term Safety in TransplantRecruiting
TransplantationIM103-116A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-BasedRecruiting
Renal Transplant (Pediatric), Pediatric StudiesIM103-144Phase II Pharmacokinetics, Efficacy, and Safety of Belatacept in Pediatric Renal Transplant RecipientsRecruiting
ColitisIM129-005Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative ColitisRecruiting
Crohn's DiseaseIM129-008Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's DiseaseRecruiting
Rheumatoid ArthritisIM133-066Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid ArthritisRecruiting
Idiopathic Pulmonary Fibrosis, Lung DiseaseIM136-003Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary FibrosisRecruiting
Diabetes (Adult)MB002-002An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With LipodystrophyRecruiting
Diabetes (Pediatric), Pediatric StudiesMB102-091PK Study of Dapagliflozin in Pediatric Subjects With T2DMRecruiting
Diabetes (Adult)MB102-129Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 DiabetesRecruiting